At this time, posts about Antrogen are rapidly increasing on portals and stock communities, while foreign investors are tentatively reported to have sold a net 1,767 shares today. Antrogen is known as a company that develops and sells stem cell therapeutics.

As of 11:30 AM on the 28th, Antrogen's stock price is 62,700 KRW, down 1.26% from the previous day, with a trading volume of 350,139 shares, which is about 14.78% of the 5-day average trading volume. On May 21, Antrogen became a market issue with the headline "Diabetic Foot Ulcer Treatment Receives FDA Approval, Surges for Second Day."

In addition to Antrogen, posts by investors are also surging for Ubicare (032620), Codem (224060), and YBMnet (057030).

※Source: AI Investment Assistant AI Lassi

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.




This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing